Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative (MRD-negative) complete remission (CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors asso...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Blood Ročník 133; číslo 15; s. 1652
Hlavní autoři:	Hay, Kevin A, Gauthier, Jordan, Hirayama, Alexandre V, Voutsinas, Jenna M, Wu, Qian, Li, Daniel, Gooley, Ted A, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S, Hawkins, Reed M, Vakil, Aesha, Steinmetz, Rachel N, Schoch, Gary, Chapuis, Aude G, Till, Brian G, Kiem, Hans-Peter, Ramos, Jorge D, Shadman, Mazyar, Cassaday, Ryan D, Acharya, Utkarsh H, Riddell, Stanley R, Maloney, David G, Turtle, Cameron J
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 11.04.2019
Témata:	Adult Antigens, CD19 - immunology Disease-Free Survival Female Hematopoietic Stem Cell Transplantation Humans Immunotherapy, Adoptive - methods Lymphocyte Depletion Male Middle Aged Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Chimeric Antigen Remission Induction - methods Salvage Therapy - methods Young Adult
ISSN:	1528-0020, 1528-0020
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!